Cargando…

Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement

Peri-procedural myocardial injury (PPMI) is a common complication after transcatheter valve replacement (TAVR), often remaining clinically silent. The role of valve type on PPMI and the association between PPMI and mortality are still unclear. We sought to evaluate predictors and outcome of PPMI aft...

Descripción completa

Detalles Bibliográficos
Autores principales: De Marzo, Vincenzo, Crimi, Gabriele, Vercellino, Matteo, Benenati, Stefano, Pescetelli, Fabio, Della Bona, Roberta, Sarocchi, Matteo, Canepa, Marco, Balbi, Manrico, Porto, Italo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481174/
https://www.ncbi.nlm.nih.gov/pubmed/33963455
http://dx.doi.org/10.1007/s00380-021-01861-8
_version_ 1784576627164839936
author De Marzo, Vincenzo
Crimi, Gabriele
Vercellino, Matteo
Benenati, Stefano
Pescetelli, Fabio
Della Bona, Roberta
Sarocchi, Matteo
Canepa, Marco
Balbi, Manrico
Porto, Italo
author_facet De Marzo, Vincenzo
Crimi, Gabriele
Vercellino, Matteo
Benenati, Stefano
Pescetelli, Fabio
Della Bona, Roberta
Sarocchi, Matteo
Canepa, Marco
Balbi, Manrico
Porto, Italo
author_sort De Marzo, Vincenzo
collection PubMed
description Peri-procedural myocardial injury (PPMI) is a common complication after transcatheter valve replacement (TAVR), often remaining clinically silent. The role of valve type on PPMI and the association between PPMI and mortality are still unclear. We sought to evaluate predictors and outcome of PPMI after TAVR, and the impact of self-expandable valve (SEV) vs. balloon-expandable valve (BEV) deployment on PPMI. Consecutive patients who underwent successful TAVR in a single-center from January 2014 to December 2019 were included. PPMI was defined according to a modified Valve Academic Research Consortium (VARC)-2 definition as a post-procedure elevation of troponin (with a peak value ≥ 15-times the upper-reference limit) < 72 h after TAVR. We included 596 patients, of whom 258 (43.3%) were men. Mean age was 83.4 ± 5.5 years. We deployed 368 (61.7%) BEV and 228 (38.3%) SEV. PPMI was observed in 471 (79.0%) patients. At multivariable analysis, SEV (OR 2.70, 95% CI 1.64–4.55, p < 0.001), creatinine clearance (OR 0.98, 95% CI 0.97–1.00, p = 0.011), and baseline ejection fraction (OR 1.05, 95% CI 1.02–1.07, p < 0.001) were independent predictors of PPMI; these findings were also confirmed using a propensity-weighted analysis. Thirty-day and 1-year all-cause mortality rates were 2.5% and 8.1%, respectively. No associations between PPMI and 30-day (p = 0.488) or 1-year (p = 0.139) all-cause mortality were found. Independent predictors of 30-day mortality were increasing EUROSCORE II (HR 1.16 per score point, 95% CI 1.08–1.19, p < 0.001) and life-threatening/major bleeding complications (HR 5.87, 95% CI 1.28–26.58, p = 0.019), whereas EUROSCORE II (HR 1.08, 95% CI 1.04–1.13, p = 0.031) and acute kidney injury (HR 2.59, 95% CI 1.20–5.35, p = 0.020) were related to 1-year mortality. PPMI is frequent after TAVR, but it does not affect 30-day or 1-year all-cause mortality. SEV implantation is associated with an increased frequency of PPMI.
format Online
Article
Text
id pubmed-8481174
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-84811742021-10-08 Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement De Marzo, Vincenzo Crimi, Gabriele Vercellino, Matteo Benenati, Stefano Pescetelli, Fabio Della Bona, Roberta Sarocchi, Matteo Canepa, Marco Balbi, Manrico Porto, Italo Heart Vessels Original Article Peri-procedural myocardial injury (PPMI) is a common complication after transcatheter valve replacement (TAVR), often remaining clinically silent. The role of valve type on PPMI and the association between PPMI and mortality are still unclear. We sought to evaluate predictors and outcome of PPMI after TAVR, and the impact of self-expandable valve (SEV) vs. balloon-expandable valve (BEV) deployment on PPMI. Consecutive patients who underwent successful TAVR in a single-center from January 2014 to December 2019 were included. PPMI was defined according to a modified Valve Academic Research Consortium (VARC)-2 definition as a post-procedure elevation of troponin (with a peak value ≥ 15-times the upper-reference limit) < 72 h after TAVR. We included 596 patients, of whom 258 (43.3%) were men. Mean age was 83.4 ± 5.5 years. We deployed 368 (61.7%) BEV and 228 (38.3%) SEV. PPMI was observed in 471 (79.0%) patients. At multivariable analysis, SEV (OR 2.70, 95% CI 1.64–4.55, p < 0.001), creatinine clearance (OR 0.98, 95% CI 0.97–1.00, p = 0.011), and baseline ejection fraction (OR 1.05, 95% CI 1.02–1.07, p < 0.001) were independent predictors of PPMI; these findings were also confirmed using a propensity-weighted analysis. Thirty-day and 1-year all-cause mortality rates were 2.5% and 8.1%, respectively. No associations between PPMI and 30-day (p = 0.488) or 1-year (p = 0.139) all-cause mortality were found. Independent predictors of 30-day mortality were increasing EUROSCORE II (HR 1.16 per score point, 95% CI 1.08–1.19, p < 0.001) and life-threatening/major bleeding complications (HR 5.87, 95% CI 1.28–26.58, p = 0.019), whereas EUROSCORE II (HR 1.08, 95% CI 1.04–1.13, p = 0.031) and acute kidney injury (HR 2.59, 95% CI 1.20–5.35, p = 0.020) were related to 1-year mortality. PPMI is frequent after TAVR, but it does not affect 30-day or 1-year all-cause mortality. SEV implantation is associated with an increased frequency of PPMI. Springer Japan 2021-05-07 2021 /pmc/articles/PMC8481174/ /pubmed/33963455 http://dx.doi.org/10.1007/s00380-021-01861-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
De Marzo, Vincenzo
Crimi, Gabriele
Vercellino, Matteo
Benenati, Stefano
Pescetelli, Fabio
Della Bona, Roberta
Sarocchi, Matteo
Canepa, Marco
Balbi, Manrico
Porto, Italo
Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement
title Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement
title_full Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement
title_fullStr Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement
title_full_unstemmed Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement
title_short Impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement
title_sort impact of bioprosthetic valve type on peri-procedural myocardial injury and mortality after transcatheter aortic valve replacement
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481174/
https://www.ncbi.nlm.nih.gov/pubmed/33963455
http://dx.doi.org/10.1007/s00380-021-01861-8
work_keys_str_mv AT demarzovincenzo impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement
AT crimigabriele impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement
AT vercellinomatteo impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement
AT benenatistefano impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement
AT pescetellifabio impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement
AT dellabonaroberta impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement
AT sarocchimatteo impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement
AT canepamarco impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement
AT balbimanrico impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement
AT portoitalo impactofbioprostheticvalvetypeonperiproceduralmyocardialinjuryandmortalityaftertranscatheteraorticvalvereplacement